[![HUB Organoids](https://blog.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "HUB Organoids")](https://huborganoids.nl/) ![merk-m-logo-blue](https://blog.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png) - [services](https://huborganoids.nl/services) - [services overview](https://www.huborganoids.nl/services-overview/) - [drug screening](https://www.huborganoids.nl/services/hub-drug-screening/) - [model and assay development](https://www.huborganoids.nl/services/) - [clinical trials in a dish](https://www.huborganoids.nl/hub-organoid-clinical-trial-in-a-dish/) - [Technology](https://huborganoids.nl/hub-technology) - [Company](https://huborganoids.nl/about) - [about us](https://huborganoids.nl/about) - [Careers](https://huborganoids.nl/careers) - [events](https://www.huborganoids.nl/meet-us/) - [latest news](https://www.huborganoids.nl/news-insights-2/) - [Resources](https://huborganoids.nl/resources/) - [Blog](https://blog.huborganoids.nl) - [license program](https://www.huborganoids.nl/licenses/) - [Contact](https://resources.huborganoids.nl/contact-hub) [discover organoid services](https://www.huborganoids.nl/services-overview/) - [services](https://huborganoids.nl/services) - [services overview](https://www.huborganoids.nl/services-overview/) - [drug screening](https://www.huborganoids.nl/services/hub-drug-screening/) - [model and assay development](https://www.huborganoids.nl/services/) - [clinical trials in a dish](https://www.huborganoids.nl/hub-organoid-clinical-trial-in-a-dish/) - [Technology](https://huborganoids.nl/hub-technology) - [Company](https://huborganoids.nl/about) - [about us](https://huborganoids.nl/about) - [Careers](https://huborganoids.nl/careers) - [events](https://www.huborganoids.nl/meet-us/) - [latest news](https://www.huborganoids.nl/news-insights-2/) - [Resources](https://huborganoids.nl/resources/) - [Blog](https://blog.huborganoids.nl) - [license program](https://www.huborganoids.nl/licenses/) - [Contact](https://resources.huborganoids.nl/contact-hub) # HUB's blog ![The Binding Bias: How Organoids Are Redefining What Matters in ADC Efficacy](https://blog.huborganoids.nl/hubfs/social-blog-the-binding-bias.jpg) ### [The Binding Bias: How Organoids Are Redefining What Matters in ADC Efficacy](https://blog.huborganoids.nl/the-binding-bias-how-organoids-are-redefining-what-matters-in-adc-efficacy) Published by HUB Organoids on Oct 13, 2025 Antibody–drug conjugates (ADCs) are designed to bring the precision of targeted therapy together with the potency of cytotoxic payloads. Naturally, much of the focus during ADC development has been on binding - ensuring that the antibody component efficiently and specifically recognizes its antigen ... [read more](https://blog.huborganoids.nl/the-binding-bias-how-organoids-are-redefining-what-matters-in-adc-efficacy) ![Ask the Expert: Inside the inFOCUS Assay for IBD Drug Discovery](https://blog.huborganoids.nl/hubfs/ask-the-expert-javier.jpg) ### [Ask the Expert: Inside the inFOCUS Assay for IBD Drug Discovery](https://blog.huborganoids.nl/ask-the-expert-inside-the-infocus-assay-a-novel-approach-to-ibd-drug-discovery) Published by HUB Organoids on May 27, 2025 In this "Ask the Expert" interview, Dr. Javier Frias Aldeguer, Senior ... [read more](https://blog.huborganoids.nl/ask-the-expert-inside-the-infocus-assay-a-novel-approach-to-ibd-drug-discovery) ![Regulators Embrace Organoids: Inside the FDA’s Shift Away from Animal Model](https://blog.huborganoids.nl/hubfs/social-fda-organoids.jpg) ### [Regulators Embrace Organoids: Inside the FDA’s Shift Away from Animal Model](https://blog.huborganoids.nl/regulators-embrace-organoids) Published by HUB Organoids on May 21, 2025 Last week, the FDA announced a transformative shift in drug ... [read more](https://blog.huborganoids.nl/regulators-embrace-organoids) ![The KRAS Conundrum: Challenges and strategies for targeted therapies in cancer](https://blog.huborganoids.nl/hubfs/social-media-KRAS-Conundrum.jpg) ### [The KRAS Conundrum: Challenges and strategies for targeted therapies in cancer](https://blog.huborganoids.nl/the-kras-conundrum-the-challenges-and-strategies-for-targeted-therapies-in-cancer) Published by Dnyanada Sahasrabudhe on Jul 23, 2024 KRAS is a proto-oncogene that is crucial in regulating cell growth ... [read more](https://blog.huborganoids.nl/the-kras-conundrum-the-challenges-and-strategies-for-targeted-therapies-in-cancer) ![Ask the Expert: How can patient-derived organoids accelerate KRAS drug development?](https://blog.huborganoids.nl/hubfs/ask-the-expert-yasmine-1.jpg) ### [Ask the Expert: How can patient-derived organoids accelerate KRAS drug development?](https://blog.huborganoids.nl/ask-the-expert-how-can-patient-derived-organoids-accelerate-kras-drug-development) Published by HUB Organoids on Jul 5, 2024 In this edition of Ask the Expert, featuring Dr. Yasmine Abouleila, ... [read more](https://blog.huborganoids.nl/ask-the-expert-how-can-patient-derived-organoids-accelerate-kras-drug-development) ![Ask the experts: Revolutionizing Oncology Drug Development with Organoid Technology](https://blog.huborganoids.nl/hubfs/assets2024/ask-the-expert-robert.jpg) ### [Ask the experts: Revolutionizing Oncology Drug Development with Organoid Technology](https://blog.huborganoids.nl/ask-the-experts-potential-of-organoids-in-oncology-research) Published by HUB Organoids on May 7, 2024 This "Ask the Experts" feature delves into the pressing inquiries ... [read more](https://blog.huborganoids.nl/ask-the-experts-potential-of-organoids-in-oncology-research) ![A beginner’s guide to Inflammatory Bowel Diseases (IBD)](https://blog.huborganoids.nl/hubfs/inflammatory-bowel-disease-organoids-1.jpg) ### [A beginner’s guide to Inflammatory Bowel Diseases (IBD)](https://blog.huborganoids.nl/inflammatory-bowel-disease-organoids) Published by HUB Organoids on Feb 26, 2024 Inflammatory Bowel Disease (IBD) is a complex condition that affects ... [read more](https://blog.huborganoids.nl/inflammatory-bowel-disease-organoids) ![Decoding adult stem cells: exploring the hallmarks of stemness](https://blog.huborganoids.nl/hubfs/SocialMedia-Blog-decoding-adult-stem-cells%20(1).jpg) ### [Decoding adult stem cells: exploring the hallmarks of stemness](https://blog.huborganoids.nl/the-six-hallmarks-of-adult-stem-cells) Published by HUB Organoids on Feb 19, 2024 Discover the 6 hallmarks of stemness in adult tissue Mammalian organ ... [read more](https://blog.huborganoids.nl/the-six-hallmarks-of-adult-stem-cells) ![Ask the Experts – organoid & immune cell co-cultures for immunotherapy](https://blog.huborganoids.nl/hubfs/Ask%20the%20Expert-linkedin-blog%20image%20(1).jpg) ### [Ask the Experts – organoid & immune cell co-cultures for immunotherapy](https://blog.huborganoids.nl/ask-the-experts-organoid-and-immune-cell-co-cultures-for-immunotherapy) Published by HUB Organoids on Jun 23, 2023 In this post of our "Ask the Experts" series, we provide ... [read more](https://blog.huborganoids.nl/ask-the-experts-organoid-and-immune-cell-co-cultures-for-immunotherapy) ![PDO Screen – Patient-derived Organoids meet Cancer Modeling](https://blog.huborganoids.nl/hubfs/organoid-stained-dapi.png) ### [PDO Screen – Patient-derived Organoids meet Cancer Modeling](https://blog.huborganoids.nl/pdo-screen-patient-derived-organoids-meet-cancer-modeling) Published by HUB Organoids on Mar 21, 2023 Discover how patient-derived organoids can revolutionize oncology ... [read more](https://blog.huborganoids.nl/pdo-screen-patient-derived-organoids-meet-cancer-modeling) [View Older Posts](https://blog.huborganoids.nl/page/2) ![HUB Organoids](https://blog.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "HUB Organoids") [Privacy Policy](https://huborganoids.nl/privacy-policy) HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany ***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.*